The indirect effects of virus infections

Reviews in Medical Virology

Volumn 13, Issue 1, 2003, Pages 1-3

  Griffiths, Paul ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ALPHA INTERFERON; ANTIVIRUS AGENT; VIRUS VACCINE;

ALLOGRAFT; CAUSE OF DEATH; CLINICAL FEATURE; CLINICAL TRIAL; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; CYTOTOXIC T LYMPHOCYTE; EDITORIAL; EPIDEMIC; ERYTHEMA MULTIFORME; GENITAL HERPES; GRAFT REJECTION; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; INFLUENZA; MEASLES; MORTALITY; OPPORTUNISTIC INFECTION; T LYMPHOCYTE ACTIVATION; VIREMIA; VIRUS CARRIER; VIRUS INFECTION;

CYTOMEGALOVIRUS INFECTIONS; ERYTHEMA MULTIFORME; HEPATITIS C; HIV INFECTIONS; HUMANS; INFLUENZA, HUMAN; MEASLES; VIRUS DISEASES;

EID: 0037241094     PISSN: 10529276     EISSN: None     Source Type: Journal    
DOI: 10.1002/rmv.385     Document Type: Editorial

References (31)

1. Rubin RH. The indirect effects of cytomegalovirus infection on the outcome of organ transplantation. JAMA 1989; 261(24): 3607-3609.
2. Balfour HH, Jr., Chace BA, Stapleton JT, Simmons RL, Fryd DS. A randomized, placebo-controlled trial of oral acyclovir for the prevention of cytomegalo-virus disease in recipients of renal allografts. New England Journal of Medicine 1989; 320(21): 1381-1387.
3. Lowance D, Neumayer HH, Legendre CM, Squifflet JP, Kovarik J, Brennan PJ, et al. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group. New England Journal of Medicine 1999; 340(19): 1462-1470.
4. Meyers JD, Ljungman P, Fisher LD. Cytomegalo-virus excretion as a predictor of cytomegalovirus disease after marrow transplantation: importance of cytomegalovirus viremia. Journal of Infectious Diseases 1990; 162(2): 373-380.
5. Prentice HG, Gluckman E, Powles RL, Ljungman P, Milpied N, Fernandez Ranada JM, et al. Impact of long-term acyclovir on cytomegalovirus infection and survival after allogeneic bone marrow transplantation. European Acyclovir for CMV Prophylaxis Study Group. Lancet 1994; 343(8900): 749-753.
6. Valantine HA, Gao SZ, Menon SG, Renlund DG, Hunt SA, Oyer P, et al. Impact of prophylactic immediate posttransplant ganciclovir on development of transplant atherosclerosis: a post hoc analysis of a randomized, placebo-controlled study. Circulation 1999; 100(1): 61-66.
7. Lemstrom K, Sihvola R, Bruggeman C, Hayry P, Koskinen P. Cytomegalovirus infection-enhanced cardiac allograft vasculopathy is abolished by DHPG prophylaxis in the rat. Circulation 1997; 95(12): 2614-2616.
8. Whittle HC, Dossetor J, Oduloju A, Bryceson AD, Greenwood BM. Cell-mediated immunity during natural measles infection. J Clin Invest 1978; 62(3): 678-684.
9. Coovadia HM, Wesley A, Brain P. Immunological events in acute measles influencing outcome. Arch Dis Child 1978; 53(11): 861-867.
10. Akramuzzaman SM, Cutts FT, Wheeler JG, Hossain MJ. Increased childhood morbidity after measles is short-term in urban Bangladesh. Am J Epidemiol 2000; 151(7): 723-735.
11. Von Pirquet C. Das verhalten der kutanen tuberculin-reacktion wahrend der masern. Dtsch Med Wochenschr 1908; (34): 1297-1300.
12. Tamashiro VG, Perez HH, Griffin DE. Prospective study of the magnitude and duration of changes in tuberculin reactivity during uncomplicated and complicated measles. Pediatr Infect Dis J 1987; 6(5): 451-454.
13. Arneborn P, Biberfeld G. T-lymphocyte subpopulations in relation to immunosuppression in measles and varicella. Infect Immun 1983; 39(1): 29-37.
14. Griffin DE, Ward BJ. Differential CD4 T cell activation in measles. J Infect Dis 1993; 168(2): 275-281.
15. Aaby P, Samb B, Simondon F, Seck AM, Knudsen K, Whittle H. Non-specific beneficial effect of measles immunisation: analysis of mortality studies from developing countries. BMJ 1995; 311(7003): 481-485.
16. Fleming DM. The contribution of influenza to combined acute respiratory infections, hospital admissions, and deaths in winter. Commun Dis Public Health 2000; 3(1): 32-38.
17. Gurfinkel EP, de la Fuente RL, Mendiz O, Mautner B. Influenza vaccine pilot study in acute coronary syndromes and planned percutaneous coronary interventions: the FLU Vaccination Acute Coronary Syndromes (FLUVACS) Study. Circulation 2002; 105(18): 2143-2147.
18. Nordin J, Mullooly J, Poblete S, Strikas R, Petrucci R, Wei F, et al. Influenza vaccine effectiveness in preventing hospitalizations and deaths in persons 65 years or older in Minnesota, New York, and Oregon: data from 3 health plans. J Infect Dis 2001; 184(6): 665-670.
19. Siscovick DS, Raghunathan TE, Lin D, Weinmann S, Arbogast P, Lemaitre RN, et al. Influenza vaccination and the risk of primary cardiac arrest. Am J Epidemiol 2000; 152(7): 674-677.
20. Whitley RJ, Hayden FG, Reisinger KS, Young N, Dutkowski R, Ipe D, et al. Oral oseltamivir treatment of influenza in children. Pediatr Infect Dis J 2001; 20(2): 127-133.
21. Morishima T, Togashi T, Yokota S, Okuno Y, Miyazaki C, Tashiro M, et al. Encephalitis and encephalopathy associated with an influenza epidemic in Japan. Clin Infect Dis 2002; 35(5): 512-517.
22. Zoulim F, Chevallier M, Maynard M, Trepo C. Clinical consequences of hepatitis C virus infection. Reviews in Medical Virology. In press.
23. Misiani R, Bellavita P, Fenili D, Vicari O, Marchesi D, Sironi PL, et al. Interferon alfa-2a therapy in cryoglobulinemia associated with hepatitis C virus. N Engl J Med 1994; 330(11): 751-756.
24. Zuckerman E, Zuckerman T, Sahar D, Streichman S, Attias D, Sabo E, et al. The effect of antiviral therapy on t(14;18) translocation and immunoglobulin gene rearrangement in patients with chronic hepatitis C virus infection. Blood 2001; 97(6): 1555-1559.
25. Hermine O, Lefrere F, Bronowicki JP, Mariette X, Jondeau K, Eclache-Saudreau V, et al. Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection. N Engl J Med 2002; 347(2): 89-94.
26. Trepo C, Guillevin L. Polyarteritis nodosa and extrahepatic manifestations of HBV infection: the case against autoimmune intervention in pathogenesis. J Autoimmun 2001; 16(3): 269-274.
27. Tatnall FM, Schofield JK, Leigh IM. A double-blind, placebo-controlled trial of continuous acyclovir therapy in recurrent erythema multiforme. Br J Dermatol 1995; 132(2): 267-270.
28. D'Agati V, Appel GB. HIV infection and the kidney. J Am Soc Nephrol 1997; 8(1): 138-152.
29. Neuenburg JK, Brodt HR, Herndier BG, Bickel M, Bacchetti P, Price RW, et al. HIV-Related Neuropathology, 1985 to 1999: Rising Prevalence of HIV Encephalopathy in the Era of Highly Active Antiretroviral Therapy. J Acquir Immune Defic Syndr 2002; 31(2): 171-177.
30. Akdis CA, Blaser K. Mechanisms of interleukin-10-mediated immune suppression. Immunology 2001; 103(2): 131-136.
31. Kaiser L, Fritz RS, Straus SE, Gubareva L, Hayden FG. Symptom pathogenesis during acute influenza: interleukin-6 and other cytokine responses. J Med Virol 2001; 64(3): 262-268.